Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEPA44
- Development stage
- Unknown
- Lead developer
- Tasly Biopharmaceuticals
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
HEPA44 is a therapeutic synthetic peptide vaccine developed by Tasly Biopharma for the treatment of chronic Hepatitis B. It is a water-insoluble polypeptide composed of 44 artificially designed linear peptides derived from Hepatitis B virus (HBV) protein sequences. Designed using an epitope-based approach, it incorporates various immune response epitopes from different HBV antigens. Clinical trials in China (Phase I and II) have demonstrated high HBeAg serological conversion rates, a favorable safety profile, and long-term persistence without viral rebound or drug resistance. Tasly Biopharma is currently pursuing an Investigational New Drug (IND) application with the FDA to initiate clinical trials in the United States.
Beyond the preview
Go deeper on HEPA44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEPA44.